These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32492043)

  • 21. DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during Starvation-Induced Autophagy.
    Nguyen TB; Louie SM; Daniele JR; Tran Q; Dillin A; Zoncu R; Nomura DK; Olzmann JA
    Dev Cell; 2017 Jul; 42(1):9-21.e5. PubMed ID: 28697336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
    Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
    BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
    Mizuno R; Miyajima A; Oya M
    Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
    [No Abstract]   [Full Text] [Related]  

  • 26. Temsirolimus: a safety and efficacy review.
    Bukowski RM
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
    Wang X; Hawk N; Yue P; Kauh J; Ramalingam SS; Fu H; Khuri FR; Sun SY
    Cancer Biol Ther; 2008 Dec; 7(12):1952-8. PubMed ID: 18981735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
    Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways.
    Zhan YH; Liu J; Qu XJ; Hou KZ; Wang KF; Liu YP; Wu B
    Asian Pac J Cancer Prev; 2012; 13(6):2739-44. PubMed ID: 22938451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysophosphatidic acid represses autophagy in prostate carcinoma cells.
    Genc GE; Hipolito VEB; Botelho RJ; Gumuslu S
    Biochem Cell Biol; 2019 Aug; 97(4):387-396. PubMed ID: 30403494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [PI3K-AKT-mTOR pathway and cancer].
    Coutte L; Dreyer C; Sablin MP; Faivre S; Raymond E
    Bull Cancer; 2012 Feb; 99(2):173-80. PubMed ID: 21742593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid in Renal Carcinoma: Queen Bee to Target?
    Tan SK; Welford SM
    Trends Cancer; 2020 Jun; 6(6):448-450. PubMed ID: 32459999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.